The similarity between ADRB1 and ADRB2 and the affinity of beta-blockers toward these receptors could explain the confusing results in such studies.[30] Furthermore, NSBBs have been shown to have more survival benefit than selective beta-blockers in ovarian cancer.[18]. This evidence concerns the gene ADRB1 and ovarian cancer.